Home Companies Catalysts Deep Dives
Elocta efmoroctocog alfa APPROVED
Drug Profile
ModalityRecombinant protein
RouteIV
Therapy AreaHematology
Launch2014-06-06
Peak Sales Est$300M
Formulations[{"id":"elocta-iv","doses":"25-65 IU/kg every 3-5 days","route":"IV","device":"Reconstitution vial",
Companies
SOBI (LICENSEE)50%
Revenue History
PeriodRevenue ($M)
2024$200M
Programs (1)
IndicationStageKey StudyRegional Status
Hemophilia A prophylaxisAPPROVEDA-LONG[{"stage":"APPROVED","region":"US","approval_date":"2014-06-06"},{"stage":"APPRO
Clinical Studies (1)
A-LONG PHASE3
COMPLETED · n=165
Primary EP: [{"id":"along-ep1","name":"Annualized bleeding rate (ABR) on individualized prophylaxis","type":"PRIMARY","unit":"bleeds/year","results":[{"ci":"2.3-3.7","arm":"along-ind","label":"Mean ABR 2.9 (media
Safety: 0 inhibitors in all 165 previously treated patients. No serious treatment-related AEs. In previously untreated patients (Kids A-LONG), ~33% inhibitor rate (consistent with class rate for any FVIII). V
NCT01181128
Notes
Standard half-life rFVIII-Fc for hemophilia A. SOBI markets as Elocta (ex-US), Sanofi/Bioverativ as Eloctate (US). Being cannibalized by Altuvoct/Altuviiio (extended half-life) and non-factor therapies (Hemlibra). Legacy product in managed decline. Still generates meaningful revenue from established patient base.
Data from Supabase · Updated 2026-03-24